Bio-Techne Corporation cash flow to debt ratio of 64.76% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Bio-Techne Corporation's free cash flow has increased 8.66% from $236.10M last year to $256.55M, signaling increasing performance

Bio-Techne Corporation's debt to equity ratio is 0.14, which means that the company's assets are healthy financed, signaling financial stability.

Bio-Techne Corporation's debt has decreased relative to shareholder equity from 0.20 last year to 0.14 today, signaling strengthened financials

Bio-Techne Corporation has a net debt to EBITDA ratio of 1.30x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Bio-Techne Corporation's interest coverage ratio of 14.64 indicates that earnings with good margin can cover interest payments on company debt

Bio-Techne Corporation's profit margin has decreased (37.60%) in the last year from 14.50% to 9.05%, signaling decreasing performance

Bio-Techne Corporation's short-term assets of $608.30M exceed its short-term liabilities of $175.85M

Bio-Techne Corporation's return on assets of 4.30% is lower than the 5.00% threshold, indicating inefficient asset utilization

Bio-Techne Corporation's return on equity of 5.49%, is lower than 15.00%, indicating bad performance

Bio-Techne Corporation's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Bio-Techne Corporation had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Bio-Techne Corporation has positive free cash flow, indicating the company generates cash after capital expenditures

Bio-Techne Corporation has a free cash flow yield of 2.27%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Bio-Techne Corporation's yearly earnings has decreased 56.34% since last year from $168.10M to $73.40M, signaling decreasing performance

Bio-Techne Corporation's yearly revenue has increased 5.23% since last year from $1.16B to $1.22B, signaling increasing performance

ROIC 4.75% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Bio-Techne Corporation's 3-year revenue CAGR of 3.33% is positive, indicating growing revenue over the past 3 years

Bio-Techne Corporation had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Bio-Techne Corporation had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Bio-Techne Corporation is overvalued relative to its fair value price of 27.31 based on Discounted Cash Flow model

Bio-Techne Corporation has an earnings yield of 0.97%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Bio-Techne Corporation is overvalued relative to its fair value price of 7.91 based on EBITDA multiple model

Bio-Techne Corporation has an EV/EBITDA ratio of 53.37x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Bio-Techne Corporation is overvalued relative to its fair value price of 41.53 based on Earnings Fair Value model

Bio-Techne Corporation's earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

Bio-Techne Corporation has a price-to-book ratio of 5.39x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Bio-Techne Corporation has a price-to-sales ratio of 9.29x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue